Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, agosto 21
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
CytomX Therapeutics Inc
CTMX
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$3.28
-0.01
-0.3%
In chiusura: Aug 21, 5:00 PM EST
$3.28
N/A
Post-mercato: 4:00 PM EST
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
CytomX Therapeutics Financials
CytomX Therapeutics (CTMX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
CytomX Therapeutics Q2 EPS $(0.09) Beats $(0.11) Estimate, Sales $1.418M Miss $12.308M Estimate
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. The company reported quarterly sales of $1.418 million which
Benzinga Newsdesk
PRO
CytomX Therapeutics Q1 EPS $(0.10) Beats $(0.20) Estimate, Sales $10.258M Beat $4.713M Estimate
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.20) by 50 percent. This is a 137.04 percent decrease over earnings of $0.27 per share from
Benzinga Newsdesk
Earnings Scheduled For March 16, 2026
Benzinga Insights
PRO
CytomX Therapeutics Q4 EPS $(0.22) Misses $(0.09) Estimate, Sales $663.000K Miss $7.900M Estimate
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.09) by 136.56 percent. This is a 195.65 percent decrease over earnings of $0.23 per
Benzinga Newsdesk
PRO
CytomX Therapeutics Q3 EPS $(0.09) Misses $(0.05) Estimate, Sales $5.963M Miss $11.625M Estimate
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.05) by 95.65 percent. This is a 228.57 percent decrease over earnings of $0.07 per share
Benzinga Newsdesk
Earnings Scheduled For November 6, 2025
Benzinga Insights
Privacy Manager